Drug intelligence / Profile preview

teriparatide + raloxifene

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

Combination therapy of teriparatide and raloxifene for the treatment of postmenopausal osteoporosis. Teriparatide is a recombinant form of parathyroid hormone (PTH 1-34) that stimulates new bone formation, while raloxifene is a selective estrogen receptor modulator (SERM) that inhibits bone resorption. The combination aims to enhance bone formation and improve bone mineral density beyond what either medication can achieve alone.

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on teriparatide + raloxifene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on teriparatide + raloxifene.

Explore the full profile